We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Home CompaniesEvofem Biosciences Inc

Evofem Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0062 USD 0.00 ( 1.64%)
Last update at 2026-11-12T15:20:00Z
VOLUME
57223
Market Cap
0.98M

Momentum Score

…

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.02
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Evofem Biosciences developed and commercialized Phexxi, an on‑demand non‑hormonal vaginal gel approved by the U.S. FDA for pregnancy prevention, and focuses on women's sexual and reproductive health programs. Long‑term growth drivers include broader adoption of non‑hormonal contraceptives, potential licensing or partnership deals, and geographic expansion, which may benefit commercial traction and strategic value while offering exposure to a differentiated contraceptive approach.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
18.05M
Revenue Per Share
0.14
Gross Profit TTM
13.63M
Debt / Equity
-0.95
ROE
-387.27%
Net Debt
65.29M
ROCE
-2.23%
Diluted EPS TTM
-0.11

Insight Announcement

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 0.39M -8.86M 53.00M -76.65M -205.18M
Net income 0.39M -8.86M 52.98M -76.70M -205.19M
Selling general administrative 7.39M 11.56M 14.95M 27.56M 24.71M
Selling and marketing expenses 9.68M 9.18M 11.66M 43.95M 113.15M
Gross profit 15.07M 15.53M 11.71M 12.42M 4.19M
Reconciled depreciation 0.63M 0.76M 1.78M 1.01M 1.02M
Ebit 1.44M -7.68M -17.85M -84.12M -166.80M
Ebitda 2.06M -6.92M -16.07M -93.60M -133.14M
Depreciation and amortization 0.63M 0.76M 1.78M -9.47M 33.66M
Operating income 1.44M -7.68M -17.85M -84.12M -166.80M
Other operating expenses 18.74M 27.04M 36.06M 100.96M 175.04M
Interest expense 2.63M - - 17.96M 71.01M
Tax provision 0.00M 0.00M 0.02M 0.04M 0.02M
Interest income 0.01M 0.02M 0.03M 0.09M 0.01M
Net interest income 0.01M 0.02M 0.03M 0.09M 0.01M
Income tax expense 0.00M - 0.02M 0.04M 0.02M
Total revenue 20.18M 19.36M 18.22M 16.84M 8.24M
Total operating expenses 13.63M 23.20M 29.55M 96.55M 170.99M
Cost of revenue 5.12M 3.83M 6.51M 4.42M 4.05M
Total other income expense net -1.05M -1.18M 70.84M 7.47M -38.37M
Net income from continuing ops 0.39M -8.86M 52.98M -76.70M -205.19M
Net income applicable to common shares - - - -78.01M -206.24M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 20.27M 23.79M 10.55M 25.16M 19.24M
Intangible assets 4.35M 9.60M - - -
Other current assets 1.10M 1.20M 0.49M 2.22M 0.63M
Total liab 89.71M 95.05M 77.06M 96.96M 14.50M
Total stockholder equity -69.44M -71.26M -66.51M -71.80M 4.74M
Other current liab 5.85M 18.32M 12.08M 10.85M 3.07M
Common stock 0.01M 0.01M 0.00M 0.01M 0.02M
Capital stock 0.01M 0.01M 0.00M 0.01M 4.76M
Retained earnings -897.39M -897.66M -888.70M -938.69M -860.68M
Other assets - - - 4.12M -12.26M
Cash 0.58M 0.74M 0.58M 2.77M 7.73M
Total current liabilities 84.82M 80.45M 72.46M 93.83M 137.66M
Current deferred revenue - - - - 13.02M
Net debt 65.29M 45.97M 43.37M 68.36M 107.95M
Short term debt 65.81M 45.96M 43.37M 68.00M 111.26M
Short long term debt 54.37M 45.88M 43.27M 65.68M 108.93M
Short long term debt total 65.87M 45.97M 43.37M 71.13M 115.68M
Other stockholder equity 831.86M 829.03M 823.04M 792.19M 855.58M
Property plant equipment - - - - 11.17M
Total current assets 15.28M 13.61M 9.21M 12.70M 19.24M
Net tangible assets - - - - -58.83M
Net receivables 12.48M 9.83M 5.74M 1.13M 6.45M
Inventory 1.13M 1.58M 1.70M 5.38M 7.67M
Accounts payable 13.15M 16.17M 17.02M 14.98M 10.32M
Accumulated other comprehensive income -8.82M -2.63M -0.85M 49.53M 5.09M
Non currrent assets other 0.04M 0.04M 0.04M 4.12M -11.17M
Non current assets total 4.99M 10.18M 1.34M 12.46M 12.26M
Capital lease obligations 0.18M 0.09M 0.10M 5.44M 6.76M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.57M -0.00M -0.34M -2.69M
Change to liabilities - - - 0.00M -0.00M
Total cashflows from investing activities -0.06M -0.57M -0.00M - -2.69M
Net borrowings 1.90M -0.39M 4.49M - -
Total cash from financing activities 1.89M 4.62M 4.78M 61.94M 90.69M
Change to operating activities - - - - 15.98M
Net income 0.27M -8.86M 52.98M -76.70M -205.19M
Change in cash -0.16M 0.16M -4.20M -8.81M -58.66M
Begin period cash flow 0.74M 0.58M 4.78M 13.59M 72.25M
End period cash flow 0.58M 0.74M 0.58M 4.78M 13.59M
Total cash from operating activities -1.99M -3.88M -8.97M -70.41M -146.67M
Issuance of capital stock 0.00M 5.00M 0.00M 32.32M 91.53M
Depreciation 0.52M 0.76M 1.78M 1.01M 1.02M
Other cashflows from investing activities -0.06M -0.56M - - -
Dividends paid 0.12M - - - -
Change to inventory -0.26M 0.06M 2.11M 1.57M -0.02M
Change to account receivables -2.65M -4.09M -4.61M 5.32M -5.38M
Sale purchase of stock - - 0.00M -0.02M -
Other cashflows from financing activities 0.10M 5.00M 0.29M 35.53M 9.16M
Change to netincome - - - - 46.92M
Capital expenditures 0.01M 0.01M 0.00M 0.34M 2.94M
Change in working capital 0.58M 0.87M 4.73M 6.02M 10.58M
Stock based compensation 0.17M 0.85M 1.19M 3.31M 8.90M
Other non cash items -3.53M 2.50M -69.64M -4.06M 4.07M
Free cash flow -2.00M -3.90M -8.97M -70.75M -149.61M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EVFM
Evofem Biosciences Inc		 0.00
1.64%		 0.01 - - 0.05 8.37 2.88 25.64
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Evofem Biosciences Inc

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

7770 Regents Rd, San Diego, CA, United States, 92122-1967

858 550 1900

https://www.evofem.com

29

Name Title Year Born
Ms. Saundra Pelletier Interim Chair, Pres & CEO 1970
Mr. Justin J. File Chief Financial Officer 1970
Ms. Amy Raskopf Sr. VP of Investor Relations NA
Kathy Gallo-Doyle VP of Sales NA
Ms. Karina M. Fedasz Head of Bus. Devel. 1973
Ms. Katherine Atkinson Chief Commercial Officer NA
Ms. Saundra Pelletier Interim Chair, President & CEO 1970
Ms. Ivy Zhang CPA CFO & Secretary 1979
Ms. Ellen Thomas Chief of Staff NA
Ms. Amy Raskopf Chief Business Development Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PARA
USD 0.10
+38.58%
LUNR
USD 13.91
+14.20%
MBGL
USD 22.63
+13.60%
FRMI
USD 2.04
+12.71%
FIGR
USD 26.97
+11.49%
CDNL
USD 6.09
-59.37%
ADIG
USD 11.79
-39.79%
CTVA
USD 9.21
-24.11%
BZ
USD 12.99
-22.28%
ENVX
USD 1.98
-21.70%

Equity Sectors*

  • Basic Materials

    -1.40%

  • Communication Services

    -0.45%

  • Consumer Cyclical

    -0.55%

  • Consumer Defensive

    -0.01%

  • Energy

    -0.01%

  • Financial Services

    -0.40%

  • Financials

    -0.15%

  • Healthcare

    -1.15%

  • Industrials

    -0.46%

  • Real Estate

    -0.29%

  • Technology

    -1.22%

  • Utilities

    -0.10%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…